Error-enhancement for Arm Rehabilitation Post Stroke
Launched by UNIVERSITAIRE ZIEKENHUIZEN KU LEUVEN · Feb 7, 2022
Trial Information
Current as of August 27, 2025
Completed
Keywords
ClinConnect Summary
The overall aim of this study is to gain knowledge into the potential of error-enhancement robot training in patients with upper limb impairments in the chronic phase after stroke. Error-enhancement is characterized as unexpected external perturbation forces acting upon the upper limb during a reaching movement, causing the upper limb to deflect from the reaching pathway, and this results in errors. If one allows for repetitive reaching performance with the same systematic perturbation forces, then a decrease in errors and improvement in movement performance is expected. The robot used for ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures
- • 2. First stroke, confirmed by neurologist based on clinical and/or imaging findings
- • 3. Ischemic/hemorrhagic stroke, at least more than six months ago
- • 4. Stroke affecting the dominant/non-dominant upper limb (unilateral weakness)
- • 5. Less than 85 years old
- • 6. Having a motor impairment yet no severe spasticity in the upper limb: be able to open and close the hand 5 times and be able to flex and extend the elbow 2 times but score less than 66 (maximum) on the Fugl-Meyer Assessment.
- Exclusion Criteria:
- • 1. Having sensory aphasia (evaluated by item 9 of the National Institutes of Health Stroke Scale)
- • 2. Having apraxia (evaluated by the apraxia screen of TULIA)
- • 3. Having neglect (evaluated by the Star Cancellation Test)
- • 4. Cognitive deficit with a score under 24 out of 30 on the Mini-mental State Examination
- • 5. Shoulder pain (yes/no)
- • 6. Providing no informed consent
About Universitaire Ziekenhuizen Ku Leuven
Universitaire Ziekenhuizen KU Leuven is a leading academic medical center in Belgium, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. Affiliated with KU Leuven, one of Europe’s premier universities, the institution integrates cutting-edge scientific inquiry with high-quality patient care. It plays a pivotal role in the development and implementation of clinical trials, fostering collaboration between researchers, healthcare professionals, and industry partners to translate scientific discoveries into effective treatments. The hospital's multidisciplinary approach ensures comprehensive patient safety and ethical standards, positioning it as a trusted sponsor in the realm of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Leuven, , Belgium
Patients applied
Trial Officials
Geert Verheyden
Principal Investigator
KU Leuven
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials